GLP-1 Coverage Denied? Here's How to Fight Back

Your insurer covered your GLP-1 medication last month, and now suddenly it doesn't. Maybe your pharmacy told you the drug is no longer on your plan's formulary. Maybe you got a letter saying prior authorization is required — or that an existing authorization has been revoked. Whatever the specific trigger, you're looking at hundreds or thousands of dollars out of pocket for a medication your doctor prescribed for a real medical condition. This article explains exactly why this happens, what your insurer is legally required to do, and the concrete steps you can take to fight the denial and get your coverage reinstated.

Why GLP-1 Coverage Is So Unstable

GLP-1 medications — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) — are not one thing to insurers. They are two separate coverage questions depending on what the drug is being prescribed to treat.

The Diabetes vs. Weight-Loss Distinction Changes Everything

The FDA has approved these drugs under different brand names for different medical purposes. Ozempic and Mounjaro are approved for Type 2 diabetes management. Wegovy and Zepbound are approved for chronic weight management in people with obesity or overweight with a related condition. In many cases the active ingredient is chemically identical — the difference is the FDA-approved indication, meaning the specific medical use the drug is officially cleared for.

Insurers treat these approvals as entirely separate coverage decisions. Most commercial insurance plans cover the diabetes versions (Ozempic, Mounjaro) because diabetes is a widely recognized, clinically urgent condition with strong treatment guidelines. Many of those same plans explicitly exclude the weight-management versions (Wegovy, Zepbound), classifying them as treatments for obesity rather than disease — a distinction that has major cost implications for insurers. If your prescription was written for weight loss and your plan excludes weight-loss drugs, you will hit a wall even if someone on the same drug for diabetes would be covered without issue.

This also means a prescribing choice matters. If your doctor prescribed Ozempic for Type 2 diabetes and the insurer is now questioning coverage, the fight is different — and often easier to win — than if you were prescribed Wegovy for weight management on a plan that excludes it entirely. Knowing which situation you're in is the first step.

Formulary Changes Can Happen at Any Time

A formulary is your insurance plan's approved list of covered drugs, organized into cost tiers. Insurers are not locked into a formulary forever. Under most commercial plans, they can change the formulary at plan renewal — typically January 1 — moving a drug to a higher cost tier, adding a prior authorization requirement, or removing it entirely. Under certain circumstances, mid-year changes are also allowed, particularly if a generic becomes available or a drug's safety profile changes.

This is not illegal. It is the standard operation of how insurance formularies work. A plan that covered Ozempic at a $45 copay last year has no obligation to cover it at that level — or at all — this year. If you're confused about why your pharmacy suddenly says your insurance pays nothing, this explanation of how prescription drug coverage gaps work may help clarify what changed at the formulary level.

Get the Denial in Writing Before You Do Anything Else

Before you appeal, you need to know the exact reason your coverage was denied or terminated. Call your insurer and request the specific denial reason code and the plan's clinical coverage criteria for GLP-1 medications — in writing. You are legally entitled to both under federal law. The denial reason code is a specific code or description that identifies why coverage was refused (examples: "not medically necessary," "excluded benefit," "prior authorization required," "step therapy requirements not met"). The clinical criteria is the document that spells out exactly what your insurer requires before it will approve a GLP-1 prescription.

Write down the date and time of every call, the name of the representative you spoke with, and what they told you. If they send documents electronically, save them immediately. This paper trail becomes the foundation of your appeal.

If your situation involves a new prior authorization requirement that wasn't there before, this guide on prior authorization and how to challenge denials walks through the full process in detail.

How to Build Your Internal Appeal

An internal appeal is your formal request for the insurer to reconsider its decision, reviewed by someone within the insurance company who was not involved in the original denial. You have the right to file one under the Affordable Care Act. The insurer must respond within specific timeframes — typically 30 days for non-urgent situations and 72 hours for urgent medical situations.

The Letter of Medical Necessity Is Your Most Powerful Tool

A letter of medical necessity (LMN) is a document your prescribing physician writes that explains, in clinical terms, why this specific drug is medically required for you. A generic note saying "patient needs this medication" will almost certainly be rejected. A strong LMN needs to directly address the insurer's stated denial criteria point by point. It should include:

• Your confirmed diagnosis (Type 2 diabetes, obesity with BMI threshold, or a weight-related comorbidity like hypertension or sleep apnea)
• Your documented treatment history — what other medications were tried, for how long, and why they failed or were contraindicated
• Specific clinical guidelines supporting the use of GLP-1 medications for your condition, such as American Diabetes Association Standards of Care or American Association of Clinical Endocrinology guidelines
• A clear statement of medical necessity connecting your diagnosis to this drug and explaining why alternatives are not equivalent

Ask your doctor explicitly to respond to the denial reason your insurer gave. If the insurer said the drug is "not medically necessary," the LMN should use language that counters that framing with clinical evidence. If the insurer requires evidence of step therapy — meaning you must try a cheaper drug first — the LMN should document any prior attempts and their outcomes.

A Concrete Example

Say you were prescribed Ozempic for Type 2 diabetes at 1 mg weekly. Your insurer approved it in 2023. In January 2024, the plan moved Ozempic to a higher tier and added a new step therapy requirement: you must try and fail metformin and a sulfonylurea drug first before they'll approve Ozempic. Your out-of-pocket cost jumped from $45 to $380 per month.

You request the denial criteria in writing. You find out the plan requires documentation of 90 days of metformin therapy. Your doctor's records show you tried metformin in 2021 but stopped due to gastrointestinal side effects. Your doctor writes an LMN citing those records, explaining that the side effects made continued use clinically impractical, referencing ADA guidelines supporting GLP-1 use in patients who cannot tolerate metformin. You submit the LMN with your appeal and include the 2021 medical records as supporting documentation. That is a winnable appeal. Without that specificity, it is not.

If the Internal Appeal Fails: Request External Review

If the insurer denies your internal appeal, you have the right to an independent external review. This means an independent physician — someone with no financial relationship with your insurance company — reviews your case and makes a binding decision. The insurer must abide by it.

External review is one of the most underused rights in the healthcare system. According to the CMS External Review Process, most people covered by non-grandfathered health plans in the individual and small group markets have access to external review, either through a federally-run process or a state-run program depending on where you live. Large employer plans (ERISA plans) also generally provide external review rights, though the process varies.

For GLP-1 medications prescribed for Type 2 diabetes, external review has real teeth. There is substantial published clinical evidence and guideline support for these medications. An independent physician reviewing a denial of Ozempic for a diabetes patient who documented a failed prior therapy attempt is not working from a blank slate — they are working from guidelines that support the prescription. Denial overturn rates in external review are meaningful, particularly for denials based on medical necessity where strong clinical guidelines exist.

To request external review, you typically need to submit a written request within 4 months of receiving your final internal appeal denial. Your insurer's denial letter is required by law to explain how to initiate external review. For a full breakdown of how to navigate both internal and external appeals, see this step-by-step guide to appealing denied insurance claims.

Other Options to Consider While You Appeal

Appeals take time, and you may need your medication in the meantime. A few options worth knowing about:

Manufacturer patient assistance programs. Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) both run savings card programs for commercially insured patients. Savings cards can reduce your out-of-pocket cost significantly — sometimes to under $25 per month — while you resolve the insurance dispute. Eligibility rules apply, and these programs typically exclude Medicare and Medicaid patients.

Watch out for copay accumulator programs. If your plan uses a copay accumulator or maximizer, manufacturer coupons may not count toward your deductible or out-of-pocket maximum, which can leave you with unexpected costs. Learn how copay accumulators work and how they may affect what you actually owe.

State insurance commissioner complaints. If your insurer is not following proper appeal procedures or is violating state insurance regulations, filing a complaint with your state's insurance commissioner creates a regulatory record and sometimes accelerates resolution. Find your state commissioner through the National Association of Insurance Commissioners (NAIC) at naic.org.

What to Do Right Now

If your GLP-1 coverage was just denied or terminated, take these steps in order: First, call your insurer today and request the denial reason code and clinical criteria in writing. Second, call your prescribing physician and explain the denial — ask them to begin preparing a detailed letter of medical necessity that responds to the specific criteria. Third, ask your pharmacist about manufacturer savings programs that can bridge the cost gap while you appeal. Fourth, file your internal appeal with the LMN and supporting records as quickly as possible, noting the deadline on your denial letter. Fifth, if the internal appeal is denied, immediately request external review — this is the step most people skip, and it is often the one that works.

GLP-1 medications represent one of the most contested areas in insurance coverage right now. Formularies are changing rapidly, exclusions are common, and insurers are pushing back on costs. But the appeals process exists precisely for situations like yours, and when a prescription is clinically justified and well-documented, it is worth using every step of it.

Sources: FDA Drug Safety and Approval Information, CMS External Review Process